News from the AI & ML world
DeeperML - #genomics
|
Sam Khosroshahi@lambdalabs.com
//
References:
Fello AI
, MarkTechPost
NVIDIA is making significant strides in healthcare and robotics, leveraging the power of AI. A key development is the NVIDIA DNA LLM, designed to accelerate genomic research. This technology is set to transform how we analyze and interpret biological data, potentially leading to breakthroughs in curing diseases. NVIDIA is also working on new AI models, specifically multimodal models, to enhance physical common sense and embodied reasoning in AI systems, essential for applications like robotics.
NVIDIA's approach includes innovations like Evo 2, a large AI model for biology trained on a massive dataset of 9.3 trillion DNA base pairs, capable of not just analyzing but also generating entire genomic sequences. Furthermore, the introduction of Cosmos-Reason1, a vision-language model, aims to improve AI's ability to reason about physical environments, a critical advancement for robotics and self-driving vehicles. Dion Harris of NVIDIA provided context to Nvidia CEO Jensen Huang's GTC 2025 keynote, highlighting the company's focus on AI factories and advancements in simulation technology. Recommended read:
References :
Sam Khosroshahi@lambdalabs.com
//
References:
Fello AI
, lambdalabs.com
,
NVIDIA is pushing the boundaries of artificial intelligence in healthcare and robotics, introducing several groundbreaking advancements. One notable innovation is the DNA LLM, designed to decode the complex genetic information found in DNA, RNA, and proteins. This tool aims to transform genomic research, potentially leading to new understandings and treatments for various diseases.
The company's commitment to AI extends to robotics with the release of Isaac GR00T N1, an open-source platform for humanoid robots. This initiative is expected to accelerate innovation in the field, providing developers with the resources needed to create more advanced and capable robots. Additionally, an NVIDIA research team has developed Hymba, a family of small language models that combine transformer attention with state space models, surpassing the Llama-3.2-3B model in performance while significantly reducing cache size and increasing throughput. Recommended read:
References :
Hassan Shittu@Fello AI
//
References:
Fello AI
, lambdalabs.com
Nvidia is making significant strides in healthcare and AI infrastructure, particularly through the development of specialized large language models (LLMs). Their DNA LLM exemplifies this, aiming to revolutionize genomic research and drug discovery. This highlights AI's potential to transform medical science by enabling faster analysis and interpretation of biological data.
Lambda has been recognized as NVIDIA's 2025 Healthcare Partner of the Year for accelerating AI innovation in healthcare and biotech. John Snow Labs introduced the first commercially available Medical Reasoning LLM at NVIDIA GTC, optimized for clinical reasoning and capable of verbalizing its thought processes. Nvidia's involvement in this has helped lead the way for these healthcare specific Large Language Models. Recommended read:
References :
@blogs.nvidia.com
//
Arc Institute and Nvidia have collaborated to release Evo 2, a groundbreaking foundation model designed to understand the genetic code across all domains of life. Trained on the DNA of over 100,000 species, encompassing a vast range of life forms, Evo 2 aims to identify patterns in gene sequences that would take experimental researchers years to uncover. Developers say the model can also accurately identify disease-causing mutations in human genes and design new genomes, potentially as long as those of simple bacteria.
Arc Institute and Nvidia collaborated to develop Evo 2 and made the tool publicly accessible from Arc Institute’s GitHub and is also integrated into Nvidia’s BioNeMo framework as part of the collaboration. The model allows scientists access to a powerful new foundation model that understands the genetic code for all domains of life. Evo 2's training data, code, and model weights are also being released, making it the largest fully open source AI model of its kind. Recommended read:
References :
@ai-techpark.com
//
NVIDIA is making significant strides in the healthcare and drug discovery sectors through strategic partnerships with key industry players. Collaborations with Illumina, Mayo Clinic, IQVIA, and Arc Institute aim to accelerate the application of artificial intelligence (AI) in various healthcare domains, from genomic research to clinical development. The partnership with Illumina leverages their sequencing technology alongside NVIDIA's AI tools to develop biological foundation models, focusing on multiomic data analysis and accelerating the identification of new drug targets. These efforts are expected to enhance the speed of drug discovery and clinical research by providing powerful AI-driven resources for pharmaceutical companies.
The collaborations extend beyond genomics, with NVIDIA also partnering with the Mayo Clinic to develop next-generation pathology models powered by NVIDIA's DGX Blackwell systems and MONAI. This is intended to pave the way for personalized diagnostics and treatments, while IQVIA is using NVIDIA's AI Foundry services to build custom models that can speed up research and development. Additionally, the Arc Institute will leverage NVIDIA AI models and tools for biomedical discovery, with a focus on advancing drug discovery, synthetic biology, and disease research. These partnerships underscore the growing impact of AI in revolutionizing healthcare and improving patient outcomes. Recommended read:
References :
|
BenchmarksBlogsResearch Tools |